WO2002065834A2 - Novel formulations of carvedilol - Google Patents

Novel formulations of carvedilol Download PDF

Info

Publication number
WO2002065834A2
WO2002065834A2 PCT/US2001/050872 US0150872W WO02065834A2 WO 2002065834 A2 WO2002065834 A2 WO 2002065834A2 US 0150872 W US0150872 W US 0150872W WO 02065834 A2 WO02065834 A2 WO 02065834A2
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
acid
pharmaceutically acceptable
organic acid
formulation
Prior art date
Application number
PCT/US2001/050872
Other languages
French (fr)
Other versions
WO2002065834A8 (en
WO2002065834A3 (en
Inventor
Vlassios Andronis
Kimberly A. Lamey
Choon K. Oh
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to US10/415,671 priority Critical patent/US20040019096A1/en
Priority to CA002426811A priority patent/CA2426811A1/en
Priority to EP01273804A priority patent/EP1335707A4/en
Priority to JP2002565411A priority patent/JP2004518734A/en
Priority to AU2001297631A priority patent/AU2001297631A1/en
Publication of WO2002065834A2 publication Critical patent/WO2002065834A2/en
Publication of WO2002065834A3 publication Critical patent/WO2002065834A3/en
Publication of WO2002065834A8 publication Critical patent/WO2002065834A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Definitions

  • This invention relates to novel formulations of carvedilol and to the use of such formulations in the treatment of hypertension, congestive heart failure and angina.
  • Carvedilol is useful in the treatment of hypertension, congestive heart failure and angina.
  • the current commercial formulation for carvedilol is immediate release, and it is administered twice daily.
  • the immediate release formulation of carvedilol is rapidly and extensively absorbed following oral administration, with the terminal elimination half-life ranging between 7-10 hours.
  • a once-daily dosing formulation for carvedilol is commercially desirable, would simplify a patient's dosing regimen and may improve compliance rates.
  • carvedilol can be formulated in novel formulations for once-daily dosing.
  • the present invention provides for the use of a pharmaceutically acceptable organic acid in formulations comprising carvedilol.
  • This invention also provides for the use of such formulations for the treatment of hypertension, congestive heart failure and angina. Description of the Invention
  • compositions of carvedilol are provided in spray-dried powder form or standard drug substance form.
  • the spray-dried powder compositions are prepared using a process that involves wet milling.
  • the suspension, thus produced, is spray dried using a spray dryer or granulated using a fluid bed granulator.
  • the composition may then be formulated, for example, in the form of tablets or capsules. Orally administrated formulations are preferred.
  • the present invention provides for a formulation comprising carvedilol, which further comprises of a pharmaceutically acceptable organic acid.
  • pharmaceutically acceptable organic acid refers to organic acids which are without pharmacological effect per se, have acceptable organoleptic properties, have acceptable density, do not have an extreme pH and are preferably solid.
  • Examples include mono-carboxylic acids and poly-carboxylic acids having from 2 to 25, preferably from 2 to 10, carbon atoms; monocyclic and polycyclic aryl acids, such as benzoic acid; as well as monohydrogen, dihydrogen and metal salts of multi-valent acids.
  • a single pharmaceutically acceptable organic acid may be used, or two or more of such may be used in combination.
  • the organic acid is a C(2-l ⁇ ) a lkyl- or alkenyl- carboxylic acid having from one, two or three carboxylic acid groups, and optionally with one or more hydroxy substituents or an additional CO group in the carbon chain, for instance malonic acid, succinic acid, fumaric acid, maleic acid, adipic acid, lactic acid, levulimc acid, sorbic acid, glutamic acid, aspartic acid, oleic acid, glutaric acid, glycine, arginine or a fruit acid, such as tartaric acid, malic acid, ascorbic acid or citric acid, most preferably citric acid.
  • malonic acid succinic acid, fumaric acid, maleic acid, adipic acid, lactic acid, levulimc acid, sorbic acid, glutamic acid, aspartic acid, oleic acid, glutaric acid, glycine, arginine or a fruit acid, such as tartaric acid, malic acid
  • Spray drying of milled compositions is carried out most suitably using a spray dryer, such as Yamato GA-32 Spray Dryer [Yarnato Scientific America Inc., Orangeburg, NY].
  • granulation of milled compositions is carried out most suitably using a fluid bed granulator, such as Glatt fluid bed granulator, or a high shear granulator.
  • the spray-dried powder, thus produced, is then used in tablets for oral administration in a unit dose.
  • These oral tablets comprise conventional controlled release formulations, such as tablets, having a sustained release or an enteric coating, or otherwise modified to control the release of the active compound, for example by the inclusion of gel forming polymers or matrix forming waxes.
  • carvedilol drug substance is mixed with an organic acid in either solution or suspension to form a drug medium to subsequently layer onto pellets or granules.
  • the drug layered pellets or granules are then coated to consist of a standard seal coat, enteric coat or a sustained release coat permeable to gastrointestinal juices.
  • the controlled release formulations are prepared, for example, as described in U. S. Patent No. 4,524,060, issued June 18, 1985, and U. S. Patent No. 4,983,401, issued January 8, 1991.
  • Other controlled release formulations are described in U. S. Patent No. 4,880,830, issued November 14, 1989, and U. S. Patent No. 5,068,112, issued November 26, 1991.
  • the controlled release formulations containing carvedilol and organic acid may also be in the form of a non-compressed drug layered pellet loaded into a standard capsule. This capsule is then enteric coated for delayed release and then subsequently coated with an immediate release portion of Carvedilol for a two burst system.
  • Tablets or capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers and diluents (tableting or compression aids), lubricants, disintegrants, colorants, flavourings, and wetting agents.
  • the tablets may be coated according to techniques well known in the art.
  • oral formulations may be prepared by conventional methods of blending, filling, tableting, or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, well known in the art.
  • the present invention provides for the use of a pharmaceutically acceptable organic acid in the formulations comprising carvedilol.
  • the formulation is adapted for oral administration.
  • the formulation is presented as a unit dose. Such a formulation is taken once daily.
  • the preferred unit dosage forms include tablets or capsules comprising 25 mg or 50 mg of carvedilol; however, the present invention also includes doses from 6.25 mg to 100 mg.
  • Examples 1 & 2 - Carvedilol 50 mg Controlled Release Aqueous Film Coated Tablets The carvedilol 50 mg controlled release (CR) aqueous film coated (AFC) tablets were prepared from a carvedilol spray-dried powder which was blended with external excipients and a lubricant, compressed, and finally coated with a clear aqueous film coat followed by a Eudragit®-based coat.
  • Product CE tablets were made with fumaric acid, whereas Product CF tablets are made with citric acid.
  • Carvedilol Spray-Dried Powder consisting of: (78.06 1 )
  • Examples 3 & 4 - Carvedilol 50 mg Controlled Release Matrix Tablets The carvedilol controlled release (CR) matrix tablets (Products CG and CH) are prepared from a carvedilol granulation containing either a carvedilol spray-dried powder or standard carvedilol drug substance, respectively. A citric acid granulation is prepared separately. The desired carvedilol granulation and the citric acid granulation are blended together along with external excipients and finally a lubricant to produce the mix from which tablets are then compressed.
  • CR carvedilol controlled release
  • Carvedilol Spray-Dried Powder (78.21 4 ) consisting of:
  • Poloxamer 407 10.40 4
  • the carvedilol controlled release (CR) capsule is prepared from carvedilol drug layered pellets containing standard carvedilol drug substance, aspartic acid and Opadry Clear. The drug layered pellets are then coated with a sustained release coat, Aquacoat ECD-30, and filled into standard capsule shells for administration.
  • Carvedilol Drug Layered Pellets consisting of: (480.7)
  • the carvedilol controlled release (CR) capsule is prepared from carvedilol drug layered pellets containing standard carvedilol drug substance, aspartic acid and Opadry Clear.
  • 22.5 mg strength drug layered pellets are filled into standard capsule shells.
  • the capsules are enteric coated for the delayed release portion and a 2.5 mg strength immediate release top-coat is then applied for the initial burst effect.
  • Carvedilol Drug Layered Pellets consisting of: (432.7)
  • the bioavailability of the formulations according to the present invention are evaluated in healthy human volunteers.
  • the study is an open-label, single dose, randomized, four-period, incomplete block, crossover study. Each subject receives a single dose of the immediate release formulation in addition to single oral doses of 3 of the 4 controlled-release formulations according to a randomization schedule.
  • the regimens for the study are tabulated below:
  • Pharmacokinetic sampling for measurement of plasma carvedilol concentrations is conducted over a 48-hour period following administration of study medication in each study session. There is a washout period of at least 7 days between dosing in sessions. Female subjects return 7-10 days following dosing in the last study session for a follow-up pregnancy test. The total duration (from screening to end of the study) of each subject's participation will be five to eight weeks.
  • the primary endpoint is the AUC of carvedilol. Secondary endpoints include Cmax, Tmax, and Tl/2, as data permit.

Abstract

This invention relates to a novel formulations comprising carvedilol and methods of using these formulations to treat hypertension, congestive heart failure and angina.

Description

NOVEL FORMULATIONS OF CARVEDILOL
Field of the Invention This invention relates to novel formulations of carvedilol and to the use of such formulations in the treatment of hypertension, congestive heart failure and angina.
Background of the Invention The compound, l-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2- propanol, is known by the name " carvedilol" and is the subject of U.S. Patent No. 4,503,067 (the '067 patent), issued March 5, 1985. This compound has the following structure:
Figure imgf000002_0001
Carvedilol is useful in the treatment of hypertension, congestive heart failure and angina. The current commercial formulation for carvedilol is immediate release, and it is administered twice daily. The immediate release formulation of carvedilol is rapidly and extensively absorbed following oral administration, with the terminal elimination half-life ranging between 7-10 hours. A once-daily dosing formulation for carvedilol is commercially desirable, would simplify a patient's dosing regimen and may improve compliance rates. Thus, it is an object of the instant invention to develop a once-daily dosing formulation for carvedilol.
According to the instant invention, it has been found that carvedilol can be formulated in novel formulations for once-daily dosing.
Summary of the Invention
The present invention provides for the use of a pharmaceutically acceptable organic acid in formulations comprising carvedilol.
This invention also provides for the use of such formulations for the treatment of hypertension, congestive heart failure and angina. Description of the Invention
According to the present invention, compositions of carvedilol are provided in spray-dried powder form or standard drug substance form. The spray-dried powder compositions are prepared using a process that involves wet milling. The suspension, thus produced, is spray dried using a spray dryer or granulated using a fluid bed granulator. The composition may then be formulated, for example, in the form of tablets or capsules. Orally administrated formulations are preferred.
Importantly, the present invention provides for a formulation comprising carvedilol, which further comprises of a pharmaceutically acceptable organic acid. As used herein, the term "pharmaceutically acceptable organic acid" refers to organic acids which are without pharmacological effect per se, have acceptable organoleptic properties, have acceptable density, do not have an extreme pH and are preferably solid.
Examples include mono-carboxylic acids and poly-carboxylic acids having from 2 to 25, preferably from 2 to 10, carbon atoms; monocyclic and polycyclic aryl acids, such as benzoic acid; as well as monohydrogen, dihydrogen and metal salts of multi-valent acids. A single pharmaceutically acceptable organic acid may be used, or two or more of such may be used in combination. Preferably, the organic acid is a C(2-lθ)alkyl- or alkenyl- carboxylic acid having from one, two or three carboxylic acid groups, and optionally with one or more hydroxy substituents or an additional CO group in the carbon chain, for instance malonic acid, succinic acid, fumaric acid, maleic acid, adipic acid, lactic acid, levulimc acid, sorbic acid, glutamic acid, aspartic acid, oleic acid, glutaric acid, glycine, arginine or a fruit acid, such as tartaric acid, malic acid, ascorbic acid or citric acid, most preferably citric acid.
The wet milling process of the present invention is well known to those skilled in the art and is described in: J. A. Herbst and J. L. Sepulveda "Fundamentals of Fine and Ultrafine Grinding in a
Stirred Ball Mill" International Powder and Bulk Solids Handling and Processing, 452, May 1978 and
L. Y. Sadler III, D. A. Stanley, and D. R. Brooks "Attrition Mill Operational Characteristics" Powder Technology 12 (1975) 19-28. Spray drying of milled compositions is carried out most suitably using a spray dryer, such as Yamato GA-32 Spray Dryer [Yarnato Scientific America Inc., Orangeburg, NY]. Alternately, granulation of milled compositions is carried out most suitably using a fluid bed granulator, such as Glatt fluid bed granulator, or a high shear granulator.
The spray-dried powder, thus produced, is then used in tablets for oral administration in a unit dose. These oral tablets comprise conventional controlled release formulations, such as tablets, having a sustained release or an enteric coating, or otherwise modified to control the release of the active compound, for example by the inclusion of gel forming polymers or matrix forming waxes.
Additionally, carvedilol drug substance is mixed with an organic acid in either solution or suspension to form a drug medium to subsequently layer onto pellets or granules. The drug layered pellets or granules are then coated to consist of a standard seal coat, enteric coat or a sustained release coat permeable to gastrointestinal juices. The controlled release formulations are prepared, for example, as described in U. S. Patent No. 4,524,060, issued June 18, 1985, and U. S. Patent No. 4,983,401, issued January 8, 1991. Other controlled release formulations are described in U. S. Patent No. 4,880,830, issued November 14, 1989, and U. S. Patent No. 5,068,112, issued November 26, 1991.
The controlled release formulations containing carvedilol and organic acid may also be in the form of a non-compressed drug layered pellet loaded into a standard capsule. This capsule is then enteric coated for delayed release and then subsequently coated with an immediate release portion of Carvedilol for a two burst system. Tablets or capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers and diluents (tableting or compression aids), lubricants, disintegrants, colorants, flavourings, and wetting agents. The tablets may be coated according to techniques well known in the art.
These oral formulations may be prepared by conventional methods of blending, filling, tableting, or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, well known in the art.
Thus, the present invention provides for the use of a pharmaceutically acceptable organic acid in the formulations comprising carvedilol. The formulation is adapted for oral administration. The formulation is presented as a unit dose. Such a formulation is taken once daily. The preferred unit dosage forms include tablets or capsules comprising 25 mg or 50 mg of carvedilol; however, the present invention also includes doses from 6.25 mg to 100 mg.
No unacceptable toxicological effects are expected when carvedilol is administered in accordance with the present invention. The following examples are illustrative of the instant invention. These examples are not intended to limit the scope of this invention as defined herein above and as claimed herein below.
Examples 1 & 2 - Carvedilol 50 mg Controlled Release Aqueous Film Coated Tablets The carvedilol 50 mg controlled release (CR) aqueous film coated (AFC) tablets were prepared from a carvedilol spray-dried powder which was blended with external excipients and a lubricant, compressed, and finally coated with a clear aqueous film coat followed by a Eudragit®-based coat. Product CE tablets were made with fumaric acid, whereas Product CF tablets are made with citric acid.
Table 1 Unit Formulas for Carvedilol 50 mg CR AFC Tablet, Products CE and CF
Quantity
Ingredients ( g/Tablet)
"Carvedilol Spray-Dried Powder" consisting of: (78.061)
Carvedilol 52.071
Poloxamer 407 10.381
Povidone 5.231
Hydroxyethyl Cellulose 10.381
Purified Water q.s.
Fumaric Acid for Product CE 120.00 or Citric Acid (monohydrate) for Product CF
Dibasic Calcium Phosphate Dihydrate 155.941
Microcrystalline Cellulose 174.00
Crospovidone 60.00
Silicon Dioxide Colloidal 6.00
Magnesium Stearate 6.00
Total Weight Tablet Core 600.00
Clear Opadry YS-1-19025-A 12.00
Aqueous Dispersion of Methacrylic Acid 45.58
Copolymer, Type C (Eudragit® L30 D-55)
Triethyl Citrate 5.83
Sodium Lauryl Sulfate 1.06
Glyceryl Stearate (Imwitor 900 Powder) 0.53
Purified Water q.s.3
Total Weight Coated Tablet 665.00
Iβased on 96% label claim for the "Carvedilol Spray-Dried Powder." These levels will change based upon the % label claim achieved during the spray drying process and are adjusted during the blending step.
•^Removed during spray drying process. ■^Removed during drying.
Examples 3 & 4 - Carvedilol 50 mg Controlled Release Matrix Tablets The carvedilol controlled release (CR) matrix tablets (Products CG and CH) are prepared from a carvedilol granulation containing either a carvedilol spray-dried powder or standard carvedilol drug substance, respectively. A citric acid granulation is prepared separately. The desired carvedilol granulation and the citric acid granulation are blended together along with external excipients and finally a lubricant to produce the mix from which tablets are then compressed.
Table 2 Unit Formulas for Carvedilol 50 mg CR Matrix Tablets, Products CG and CH
Quantity (mg/Tablet)
Ingredients CG CH
Carvedilol Granulation
"Carvedilol Spray-Dried Powder" (78.214) consisting of:
Carvedilol 52.174
Poloxamer 407 10.404 —
Povidone 5.244 —
Hydroxyethyl Cellulose 10.404 —
Purified Water q.s.5 —
Carvedilol — 50.00
Hydroxypropyl Methylcellulose 77.01 95.96 Carboxymethylcellulose Sodium 38.30 47.57 Povidone 8.07 8.06
Purified Water q.s.5 q.s.->
Citric Acid Granulation
Citric Acid 104.98 104.98
Hydroxypropyl Methylcellulose 54.43 54.43 Carboxymethylcellulose Sodium 27.22 27.22 Povidone 7.78 7.78
Purified Water q.s.-> q.s.
Final Blend
Microcrystalline Cellulose 192.00 192.00 4 4
Silicon Dioxide Colloidal 6.00 6.00
Magnesium Stearate 6.00 6.00
Total Tablet Weight 600.00 600.00
4Based on 96% label claim for the "Carvedilol Spray-Dried Powder." These levels will change based upon the % label claim achieved during, the spray drying process and are adjusted during the blending step. ^Removed during processing. Example 5 - Carvedilol 25 mg Controlled Release Capsule
The carvedilol controlled release (CR) capsule is prepared from carvedilol drug layered pellets containing standard carvedilol drug substance, aspartic acid and Opadry Clear. The drug layered pellets are then coated with a sustained release coat, Aquacoat ECD-30, and filled into standard capsule shells for administration.
Ingredients (mg/Capsule)
"Carvedilol Drug Layered Pellets" consisting of: (480.7)
Carvedilol 25.0
L- Aspartic Acid 31.2
Opadry Clear 25.0
Purified Water q.s.l
Microcrystalline Cellulose Spheres 399.5
Ethylcellulose Aqueous Dispersion (Aquacoat ECD-30) 113.9
Dibutyl Sebacate 36.1
Purified Water q.s.l
Opadry Clear 1.9
Purified Water q.s.l
Size 00 Capsule Shell 118.0
Total Weight Capsule 750.6
1 Removed during drug layering or coating process.
Example 6 - Carvedilol 25 mg Controlled Release Capsule
The carvedilol controlled release (CR) capsule is prepared from carvedilol drug layered pellets containing standard carvedilol drug substance, aspartic acid and Opadry Clear.
22.5 mg strength drug layered pellets are filled into standard capsule shells. The capsules are enteric coated for the delayed release portion and a 2.5 mg strength immediate release top-coat is then applied for the initial burst effect.
Ingredients (mg/Capsule)
"Carvedilol Drug Layered Pellets" consisting of: (432.7)
Carvedilol 22.5
L- Aspartic Acid 28.1
Opadry Clear 22.5
Purified Water q s 1
Microcrystalline Cellulose Spheres 359.6
Aqueous Dispersion of Methacrylic Acid Copolymer, Type 49.7 C (Eudragit® L30 D-55)
Triethyl Citrate 5.8 Silicon Dioxide Colloidal 4.2 Sodium Lauryl Sulfate 0.4 Purified Water q.s.l
Carvedilol 2.5 L-Aspartic Acid 0.2 Opadry Clear 2.5 Purified Water q.sJ Size 1 Capsule Shell 76.0
Total Weight Capsule 574.0
1 Removed during drug layering or coating process.
in vivo Pharmacokinetic evaluation of formulations
The bioavailability of the formulations according to the present invention are evaluated in healthy human volunteers. The study is an open-label, single dose, randomized, four-period, incomplete block, crossover study. Each subject receives a single dose of the immediate release formulation in addition to single oral doses of 3 of the 4 controlled-release formulations according to a randomization schedule. The regimens for the study are tabulated below:
Figure imgf000008_0001
Pharmacokinetic sampling for measurement of plasma carvedilol concentrations is conducted over a 48-hour period following administration of study medication in each study session. There is a washout period of at least 7 days between dosing in sessions. Female subjects return 7-10 days following dosing in the last study session for a follow-up pregnancy test. The total duration (from screening to end of the study) of each subject's participation will be five to eight weeks.
The primary endpoint is the AUC of carvedilol. Secondary endpoints include Cmax, Tmax, and Tl/2, as data permit.
It is to be understood that the invention is not limited to the embodiments illustrated hereinabove and the right is reserved to the illustrated embodiments and all modifications coming within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incorporated herein by reference as though fully set forth.

Claims

What is claimed is:
1. A matrix formulation comprising carvedilol and a pharmaceutically acceptable organic acid.
2. The formulation according to claim 1 wherein the pharmaceutically acceptable organic acid is citric acid.
3. An enteric coated formulation comprising carvedilol and a pharmaceutically acceptable organic acid.
4. The formulation according to claim 3 wherein the pharmaceutically acceptable organic acid is citric acid.
5. A drug layered formulation comprising carvedilol and a pharmaceutically acceptable organic acid.
6. The formulation according to claim 5 wherein the pharmaceutically acceptable organic acid is aspartic acid.
7. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the formulation according to any one of claims 1-6.
PCT/US2001/050872 2000-10-24 2001-10-23 Novel formulations of carvedilol WO2002065834A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/415,671 US20040019096A1 (en) 2001-10-23 2001-10-23 Novel formulations of carvedilol
CA002426811A CA2426811A1 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol
EP01273804A EP1335707A4 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol
JP2002565411A JP2004518734A (en) 2000-10-24 2001-10-23 A new formulation of carvedilol
AU2001297631A AU2001297631A1 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24291100P 2000-10-24 2000-10-24
US60/242,911 2000-10-24

Publications (3)

Publication Number Publication Date
WO2002065834A2 true WO2002065834A2 (en) 2002-08-29
WO2002065834A3 WO2002065834A3 (en) 2002-10-03
WO2002065834A8 WO2002065834A8 (en) 2003-06-26

Family

ID=22916614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050872 WO2002065834A2 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol

Country Status (5)

Country Link
EP (1) EP1335707A4 (en)
JP (1) JP2004518734A (en)
AU (1) AU2001297631A1 (en)
CA (1) CA2426811A1 (en)
WO (1) WO2002065834A2 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024429A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Polymer release system
WO2003024426A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Controlled release solid dispersions
WO2007023325A2 (en) * 2005-08-26 2007-03-01 Egis Gyógyszergyár Nylvánosan Müködo Részvénytársaság Controlled release pharmaceutical composition containing carvedilol
JP2007512350A (en) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Carvedilol composition treatment and delivery methods
JP2007512375A (en) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Carvedilol free base, carvedilol salt, anhydrous form or solvate thereof, corresponding pharmaceutical composition, controlled release formulation and treatment or delivery method
EP1853280A2 (en) * 2005-02-25 2007-11-14 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
WO2008102192A2 (en) * 2007-02-23 2008-08-28 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Controlled release pharmaceutical compositions
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
WO2010037854A2 (en) * 2008-10-02 2010-04-08 Ethypharm Alcohol-resistant tablet
US7883722B2 (en) 1998-04-03 2011-02-08 Egalet Ltd. Controlled release composition
US8298581B2 (en) 2003-03-26 2012-10-30 Egalet A/S Matrix compositions for controlled delivery of drug substances
US8372387B2 (en) 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
US8449914B2 (en) 2002-11-08 2013-05-28 Egalet Ltd. Controlled release carvedilol compositions
US8609143B2 (en) 2001-09-21 2013-12-17 Egalet Ltd. Morphine polymer release system
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release
US9155758B2 (en) 2006-08-01 2015-10-13 Phrixus Pharmaceuticals, Inc. Treatment of chronic progressive heart failure
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US9884029B2 (en) 2003-03-26 2018-02-06 Egalet Ltd. Morphine controlled release system

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191028B (en) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
TWI415604B (en) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd Controlled release carvediolol formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056968A (en) * 1997-03-11 2000-05-02 Darwin Discovery Limited Pharmaceutical drug dosage forms providing different release rates
US6224909B1 (en) * 1996-09-12 2001-05-01 Roche Diagnostics Gmbh Fast decomposing pellets

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816036A1 (en) * 1998-04-09 1999-10-14 Roche Diagnostics Gmbh Production of pharmaceutical preparations with high disintegration rate containing difficultly soluble active ingredient, e.g. carvedilol
KR100336090B1 (en) * 1998-06-27 2002-05-27 윤승원 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof
DE19833119A1 (en) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Storage-stable injectable solution of vasodilator and beta blocker Carvedilol contains buffer, organic solvent, antioxidant and complexing agent
PE20001302A1 (en) * 1998-11-27 2000-11-30 Hoffmann La Roche PREPARATIONS OF A PHARMACEUTICAL COMBINATION CONTAINING CARVEDILOL AND HYDROCHLOROTHIAZIDE
JP2003514019A (en) * 1999-11-15 2003-04-15 スミスクライン・ビーチャム・コーポレイション Carvedilol methanesulfonate
JP2003528914A (en) * 2000-04-03 2003-09-30 エフ．ホフマン−ラ ロシュ アーゲー Concentrated solution of carvedilol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6224909B1 (en) * 1996-09-12 2001-05-01 Roche Diagnostics Gmbh Fast decomposing pellets
US6056968A (en) * 1997-03-11 2000-05-02 Darwin Discovery Limited Pharmaceutical drug dosage forms providing different release rates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1335707A2 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883722B2 (en) 1998-04-03 2011-02-08 Egalet Ltd. Controlled release composition
WO2003024426A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Controlled release solid dispersions
US8617605B2 (en) 2001-09-21 2013-12-31 Egalet Ltd. Polymer release system
US8609143B2 (en) 2001-09-21 2013-12-17 Egalet Ltd. Morphine polymer release system
US9694080B2 (en) 2001-09-21 2017-07-04 Egalet Ltd. Polymer release system
WO2003024429A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US9707179B2 (en) 2001-09-21 2017-07-18 Egalet Ltd. Opioid polymer release system
US8449914B2 (en) 2002-11-08 2013-05-28 Egalet Ltd. Controlled release carvedilol compositions
US9884029B2 (en) 2003-03-26 2018-02-06 Egalet Ltd. Morphine controlled release system
US8298581B2 (en) 2003-03-26 2012-10-30 Egalet A/S Matrix compositions for controlled delivery of drug substances
USRE47084E1 (en) 2003-11-25 2018-10-16 Flamel Ireland Limited Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
JP2007512375A (en) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Carvedilol free base, carvedilol salt, anhydrous form or solvate thereof, corresponding pharmaceutical composition, controlled release formulation and treatment or delivery method
JP2007512350A (en) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Carvedilol composition treatment and delivery methods
EP1691789A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US7846426B2 (en) 2005-02-25 2010-12-07 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
EP1853280A4 (en) * 2005-02-25 2008-10-29 Univ Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
EP1853280A2 (en) * 2005-02-25 2007-11-14 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
US8580245B2 (en) 2005-02-25 2013-11-12 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
WO2007023325A3 (en) * 2005-08-26 2007-06-28 Egis Gyogyszergyar Nyrt Controlled release pharmaceutical composition containing carvedilol
EA013058B1 (en) * 2005-08-26 2010-02-26 Эгиш Дьодьсердьяр Ньильваношан Мюкеде Ресвеньтаршашаг Controlled release pharmaceutical composition containing carvedilol
WO2007023325A2 (en) * 2005-08-26 2007-03-01 Egis Gyógyszergyár Nylvánosan Müködo Részvénytársaság Controlled release pharmaceutical composition containing carvedilol
US9155758B2 (en) 2006-08-01 2015-10-13 Phrixus Pharmaceuticals, Inc. Treatment of chronic progressive heart failure
WO2008102192A2 (en) * 2007-02-23 2008-08-28 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Controlled release pharmaceutical compositions
WO2008102192A3 (en) * 2007-02-23 2009-04-09 Egis Gyogyszergyar Nyilvanosan Controlled release pharmaceutical compositions
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
US8372387B2 (en) 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
AU2009299810B2 (en) * 2008-10-02 2014-08-14 Ethypharm Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules
US9492397B2 (en) 2008-10-02 2016-11-15 Ethypharm Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules
WO2010037854A3 (en) * 2008-10-02 2010-12-23 Ethypharm Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules
FR2936709A1 (en) * 2008-10-02 2010-04-09 Ethypharm Sa ALCOHOL-RESISTANT TABLETS.
WO2010037854A2 (en) * 2008-10-02 2010-04-08 Ethypharm Alcohol-resistant tablet
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release

Also Published As

Publication number Publication date
AU2001297631A8 (en) 2005-09-15
EP1335707A4 (en) 2005-07-06
CA2426811A1 (en) 2002-08-29
WO2002065834A8 (en) 2003-06-26
JP2004518734A (en) 2004-06-24
EP1335707A2 (en) 2003-08-20
AU2001297631A1 (en) 2002-09-04
WO2002065834A3 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
EP1335707A2 (en) Novel formulations of carvedilol
US7674479B2 (en) Sustained-release bupropion and bupropion/mecamylamine tablets
US8747898B2 (en) Controlled release oral dosage form
JP3806740B2 (en) Drug delivery composition
JP5739080B2 (en) Sustained release formulation of levetiracetam
US20120301541A1 (en) Compressed core for pharmaceutical composition
US20020064555A1 (en) Proton pump inhibitor formulation
EP1233768A1 (en) Carvedilol methanesulfonate
GB2128088A (en) Oral mopidamol preparations
EP1820506B1 (en) Dipyridamole extended-release formulations and process for preparing same
US20040019096A1 (en) Novel formulations of carvedilol
EP2468361B1 (en) Vildagliptin Formulations
WO1998029095A2 (en) Sustained release cisapride mini-tablet formulation
JP6148252B2 (en) New formulation
TW201206501A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
JP2023513249A (en) Omecamtib mecarbyl formulation
JP2015500853A (en) Immediate release multi-unit pellet system
US8703191B2 (en) Controlled-release pharmaceutical tablets
AU2007263261B2 (en) Galenical formulations of aliskiren and hydrochlorothiazide
EP1178780B1 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
WO2009027786A2 (en) Matrix dosage forms of varenicline
CZ287149B6 (en) Pharmaceutical preparation containing gemfibrozil
WO2007129329A2 (en) Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
WO2008038155A2 (en) Controlled-release pharmaceutical tablets
JP2009525953A (en) Sustained release formulation of divalproic acid and its derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2426811

Country of ref document: CA

Ref document number: 10415671

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002565411

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001273804

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 35/2002 UNDER (22) REPLACE "19 OCTOBER 2001 (19.10.2001)" BY "23 OCTOBER 2001 (23.10.2001)

WWP Wipo information: published in national office

Ref document number: 2001273804

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001273804

Country of ref document: EP